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Lipids are essential components of a living organism as energy source but also as
constituent of the membrane lipid bilayer. In addition fatty acid (FA) derivatives interact with
many signaling pathways. FAs have amphipathic properties and therefore require being
associated to protein for both transport and intracellular trafficking. Here we will focus on
several FA handling proteins, among which the fatty acid translocase/CD36 (FAT/CD36),
members of fatty acid transport proteins (FATPs), and lipid chaperones fatty acid-binding
proteins (FABPs). A decade of extensive studies has helped decipher the mechanism
of action of these proteins in peripheral tissue with high lipid metabolism. However,
considerably less information is available regarding their role in the brain, despite the high
lipid content of this tissue. This review will primarily focus on the recent studies that
have highlighted the crucial role of lipid handling proteins in brain FA transport, neuronal
differentiation and development, cognitive processes and brain diseases. Finally a special
focus will be made on the recent studies that have revealed the role of FAT/CD36 in brain
lipid sensing and nervous control of energy balance.
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INTRODUCTION
All mammalian cells require energy and nutrient supplies for their
proper functioning. Aside of glucose and protein, which represent
respectively the major source of energy for both the brain and the
red cells, and the critical source of nitrogen, lipids are the most
energetic source. Lipids are used almost exclusively by the body
during long term energy deprivation but represent also the major
component of plasma membranes. Therefore a sustained supply
of lipids is essential for the proper development, differentiation,
and metabolism of most cells. Fatty acids (FAs) are amphipathic
molecules that require specific buffering processes to circulate
in the plasma and cross the plasma membrane. Indeed, protein-
based transmembrane translocation and intracellular FA binding
proteins allow lipid-based molecules to access all sub cellular
compartments. Although the fine mechanism is still elusive, this
is a fundamental process by which a lipid-based molecule could
enter the cell and modulate signaling pathways and the activ-
ity of transcription factors. Some FA handling proteins such as
the fatty acid translocase FAT/CD36, fatty acid transport pro-
teins (FATPs), and lipid chaperones fatty acid-binding proteins
(FABPs) have been extensively studied in peripheral tissues but
considerably less information is available regarding their role in
the brain. This review attempts to cover their role in brain FA
transport, neuronal differentiation and development, cognition,
and energy homeostasis.
FA HANDLING PROTEINS IN BLOOD-BRAIN TRANSPORT
Brain is surrounded with the blood-brain barrier (BBB) which
provides protection against the entry of harmful substances
and allows the removal of waste produced. The BBB is com-
posed of four cell types including endothelial cells, pericytes,
astrocytes, and neurons altogether composing the neurovascu-
lar unit (Hawkins and Davis, 2005). An anatomical particularity
of the BBB is that brain microvessel endothelial cells are con-
nected by strong tight junctions that direct plasma substances
into transcellular routes and reduce the paracellular diffusion
of solutes and macromolecules (Benarroch, 2011). FA transport
across the BBB relies on two distinct mechanisms: a passive dif-
fusion through the lipid bilayer called FA flip-flop, mostly due
to FA lipophilic properties (Hamilton and Brunaldi, 2007), and
the facilitated transport of FAs that requires the presence of
saturable FA transporters. FATPs, FAT, and FABPs have been
identified in endothelial cells of the BBB. A recent study, using
human brain microvessel endothelial cell (HBMEC) monolay-
ers, demonstrated that among the different FA transporters
expressed, FATP-1 (SLC27A1), and FATP-4 (SLC27A4) are the
most abundant in HBMEC while FAT/CD36 insures the major-
ity of FA transport (Mitchell et al., 2011). FATPs are a fam-
ily of six membrane proteins; they have one transmembrane
domain with an extracellular FA binding site and an intracel-
lular ATP binding domain with acyl-CoA synthetase activity
(Mitchell and Hatch, 2011). FAT/CD36 is a membrane pro-
tein discovered in 1993 in rat isolated adipocytes (Abumrad
et al., 1993) that is expressed in many tissues and binds many
ligands: thrombospondin, an endogenous inhibitor of angiogen-
esis (Dawson et al., 1997), saturated and unsaturated FAs with
an affinity in the nanomolar range (Baillie et al., 1996), oxi-
dized low density lipoproteins (Puente Navazo et al., 1996) and
pathogenic agents such as Plasmodium falciparum (Baruch et al.,
1999).
Besides their presence in the BBB, lipid handling proteins
are also largely expressed in different brain areas (Schaffer and
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Lodish, 1994; Utsunomiya et al., 1997; Owada, 2008) and are
involved in both brain development and adult neurogenesis.
FA HANDLING PROTEINS IN BRAIN DEVELOPMENT
AND NEURONAL DIFFERENTIATION
FAs, notably polyunsaturated FAs (PUFAs), are necessary for nor-
mal development of the central nervous system (CNS) (Neuringer
et al., 1988). Indeed, brain has a lipid content of about 50% of
its dry weight suggesting an essential role of lipids in membrane
constitution and signaling pathways (Edmond, 2001; Rapoport
et al., 2001). Many psychiatric diseases such as schizophrenia,
depression, Parkinson’s disease or Alzheimer dementia (AD) are
associated with PUFA deficiency (Salvati et al., 2006; Watanabe
et al., 2007; Iwayama et al., 2010). Because PUFAs are lipophilic
molecules, their intracellular trafficking needs chaperones pro-
teins called FABPs. Among the 10 members of FABP family,
three of them have been shown to participate in the development
and function of the adult brain (Liu et al., 2010): Heart-FABP
(H-FABP; FABP-3), Epidermal-FABP (E-FABP; FABP-5), and
Brain-FABP (B-FABP; FABP-7). H-FABP is expressed during the
late phase of brain development. It could participate to neurite
formation and synapse maturation, and supports neuronal func-
tion in adult age (Sellner et al., 1995; Owada et al., 1996). E-FABP
is more expressed in neurons before and after birth suggesting
a role in neuronal differentiation. Indeed, its differential tempo-
ral expression during development is consistent with its proposed
role in the transport of long chain FAs and/or other lipophilic
ligands during neuronal differentiation and axon growth (Liu
et al., 2008). B-FABP is specifically expressed in radial glial cells
implicated in neuron migration during brain development (Feng
et al., 1994) and its expression is partially regulated by the pres-
ence of migrating neurons (Feng and Heintz, 1995; Anthony
et al., 2005). Knockout studies show that H-FABP knockout mice
present a reduction in both incorporation of arachidonic acid
(AA; 20:4 n-6) and proportion of total ω-6 FAs in the major
phospholipid classes, suggesting a role for H-FABP in ω-6 FAs
uptake and metabolism in the developing brain (Murphy et al.,
2005). B-FABP knockout leads to a decreased number in astro-
cytes, neural stem cells and early progenitor cells in developing
brain suggesting that B-FABP plays an important role in neuro-
genesis by maintaining the pool of neural stem/progenitor cells
notably in hippocampus (Watanabe et al., 2007). Contrary to
other FABPs, E-FABP knockout mice have no brain phenotype
suggesting a compensatory phenomenon with other brain FABPs
(Owada et al., 2002). Besides their important roles in brain devel-
opment, FABPs may also contribute to the proliferation of neural
progenitor cells (Boneva et al., 2011). FABPs are expressed in
astrocytes where they serve as chaperone proteins to drive PUFAs
to the nucleus and participate to the regulation of gene expres-
sion, membrane synthesis and β-oxidation and to the controlled
release of PUFAs acting as paracrine signals for newborn neurons
(Yamashima, 2012).
In addition, long-chain acyl-coA synthase 4 (LACS4; ACSL4)
has been shown to regulate neuronal differentiation. LACS4
catalyzes the formation of acyl-CoA from FAs, ATP and CoA
and plays an important role in arachidonate metabolism (Kang
et al., 1997). Docosahexaenoic acid (DHA; 22:6 n-3) and AA are
important supplements for neuronal differentiation (Kan et al.,
2007), in addition cell neogenesis requires a significant amount
of FAs to produce the lipid bilayer of the cytoplasmic membrane.
It is possible that LACS4 deficiency might interfere with AA re-
esterification into the neuronal membrane during differentiation.
Moreover, LACS4 knockout in mouse embryonic stem cells atten-
uates neuronal differentiation and neurite outgrowth induced by
growth factors (Cho, 2012).
Finally, brain expression of GPR40 (FFAR1) suggests a role in
detection of PUFAs and mediation of their metabolic or signal-
ing effects. GPR40 was discovered in 1997 by Sawzdargo et al.
(1997), and belongs to the G-protein coupled receptors (GPCR)
family which gathers many proteins with seven transmembrane
domains. The binding of PUFAs to GPR40 initiates an intracellu-
lar cascade involving phospholipase C and phosphatidylinositol
(Briscoe et al., 2003; Itoh et al., 2003; Kotarsky et al., 2003). In
mice, GPR40 is expressed in the olfactory bulb, striatum, hip-
pocampus, midbrain, hypothalamus, medulla oblongata, cerebel-
lum, and cerebral cortex (Nakamoto et al., 2012). In humans
and monkeys, GPR40 is expressed throughout the brain in neu-
rons, and its presence in astrocytes of the subventricular zone and
subgranular zone indicates a potential involvement in the regu-
lation of adult neurogenesis (Ma et al., 2007). Ma et al. showed
that GPR40 was upregulated in astrocytes and newborn neurons
after transient global cerebral ischemia in the neurogenic niche of
adult monkey hippocampus (Ma et al., 2008). This phenomenon
is associated with the increase in DHA content which might
stimulate the generation and differentiation of newborn neu-
rons through a GPR40 upregulation and CREB (c-AMP response
element-binding) activation (Yamashima, 2012).
Consequently, abnormalities in FA handling protein expres-
sion can affect the normal growth of the CNS which in turn
can lead to cognitive impairment (Bourre, 2004; Abumrad et al.,
2005) and psychiatric diseases such as schizophrenia (Watanabe
et al., 2007).
FA HANDLING PROTEINS AND COGNITIVE PROCESSES
Among the different mechanisms, FA handling proteins could
modulate cognition by influencing brain FA transport and there-
fore by modulating supply of the needed FAs to the brain. For
example AA and DHA are the major constituents of neural cell
membrane phospholipids which are derived respectively from the
dietary precursors: linoleic acid and α-linolenic acid. De novo
synthesis is very limited in Mammals, so brain composition and
function can be sensitive to dietary influences and brain trans-
port. B-FABP deletion induces a decrease by 4% in the content
of DHA and an increase by 4% in the content of AA in total
neonatal brains (Owada et al., 2006). B-FABP null mice have no
impairment of spatial learning/memory but the plus-maze test
shows a behavioral alteration that suggests an enhancement of
anxiety. This study demonstrated that the change in DHA and
AA content at the neonatal stage, although small, could be criti-
cal in the establishment of emotional disorders in adult (Owada
et al., 2006). Recently, it has been shown that CD36 null mice have
decreased levels of monounsaturated FAs in several brain phos-
pholipid pools (Song et al., 2010). CD36 null mice show normal
levels of anxiety and exploration patterns of novel environment.
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However Abumrad et al. noticed a behavioral difference in the
eight radial armmazes between CD36 null and WT mice, reflect-
ing a deficit in learning ability (Abumrad et al., 2005). It is not
clear if these changes are related to altered brain phospholipid
composition.
In addition, some lipid handling proteins are able to modu-
late neurotransmission. In a recent study, Nakamoto et al. showed
that DHA-induced antinociception via β-endorphin release may
be mediated through GPR40 signaling in the supraspinal area
(Nakamoto et al., 2012). They suggested that GPR40 signal-
ing activated by DHA or GW9508 (GPR40-selective agonist)
may lead to a Ca2+ influx and an acceleration of β-endorphin
release in nerve ending particles or synaptosomes. In fact,
intracerebroventricular injection of DHA and GW9508 signifi-
cantly reduced formalin-induced pain behavior, and those effects
were inhibited by pretreatment with anti-β-endorphin antiserum
(Nakamoto et al., 2012). Moreover, H-FABP and the intracellu-
lar form of dopamine D2 receptor (D2R) co-immunoprecipitate
in brain extracts and colocalize immunohistochemically in the
dorsal striatum (Takeuchi and Fukunaga, 2003; Shioda et al.,
2010). Dopaminergic system and particularly D2R has been
implicated in reward mechanisms and locomotor control in
the brain. H-FABP null mice have D2R dysfunction showed
by lower responsiveness to metamphetamine-induced locomotor
sensitization and enhanced haloperidol-induced catalepsy com-
pared with WT mice. H-FABP is expressed in acetylcholinergic
interneurons and of glutamatergic neuronterminals in the dorsal
striatum of mouse brain but is absent in dopamine neuron ter-
minals and spines in the same region. H-FABP null mice exhibit
no change in total D2R protein levels compared with WT, sug-
gesting that H-FABP does not alter D2R stability or turnover
in the striatum. D2R dysfunction is associated with an increase
in KCl-induced acetylcholine and glutamate release, suggesting
that H-FABP regulates dopamine-regulated Ach and Glu release
through D2R in the striatum (Shioda et al., 2010).
Finally, genomic or RNA analysis have shown that some
FABP genes are associated with psychiatric disorder, e.g., LACS2
(ACSL2) expression is upregulated in cortical regions of ratmodel
of depression (Setnik andNobrega, 2004). Moreover, expressional
changes and genetic variants of B-FABP are observed in mouse
models and in human schizophrenia (Iwayama et al., 2010).
FA HANDLING PROTEINS AS POTENTIAL
THERAPEUTIC TARGETS IN BRAIN DISEASE
As described above, FA handling proteins have an important role
in many brain functions. Increasing evidences indicate that a dys-
function or a deregulation in brain FA handling protein expres-
sion or action could play a pathogenic role inmany brain diseases.
In addition CD36 and LACS can be considered as potential ther-
apeutic targets to treat AD, bipolar disorders or Refsum disease
(RfD), which is an autosomal recessive neurologic disorder of the
lipid metabolism.
In atherosclerosis and AD, deposition of oxidized low-density
lipoproteins and Amyloid-β peptide (Aβ) triggers an inflam-
matory response through a heterodimer of Toll-like receptors 4
and 6 regulated by signals from the scavenger receptor CD36
(Stewart et al., 2010). Aβ has profound deleterious vascular effects
mediated for the most part by the reactive oxygen species (ROS)
produced by the NADPH oxidase enzyme. Recently it has been
reported that these Aβ effects are not observed in CD36 null mice
(Park et al., 2011). Park et al. suggest that CD36, localized mainly
to endothelial cells, may interact with Aβ to activate NADPH
oxidase, triggering vascular oxidative stress and cerebrovascular
dysfunction. In addition, CD36-mediated assembly of hp130Cas
complexes is an essential part of the Aβ signaling that induces
microglia migration to sites of Aβ deposition. Recently, the CD36
ligand ursolic acid was identified as a potential therapeutic agent
for AD via its ability to block Aβ-CD36 interactions (Wilkinson
et al., 2011).
In bipolar disorders, valproic acid is used as a treatment by
acting as a non-competitive inhibitor of brain microsomal LACS
(Bazinet et al., 2006). Bazinet et al. showed that this treatment
induced a decrease of arachidonoyl-CoA production by reduc-
ing the brain AA cascade. Moreover, the murine LACS (mLACS;
ACSL2) have been involved in RfD (Kee et al., 2003). RfD is
biochemically characterized by the excessive accumulation of
phytanic acid in tissues and body fluids due to the deficiency of
phytanoyl-CoA α-hydroxylase (PAHX) which normally interacts
with multiple proteins. Kee et al. propose that, in the RfD, lack
of PAHX interaction with mLACS in neural tissue may affect the
role of mLACS on lipid metabolism leading to the development
of neurological symptoms.
In summary, FA handling proteins are implicated in many
brain functions and potential diseases. However little informa-
tion were gathered regarding the implication of these proteins in
the nervous control of energy balance.
IMPLICATION OF FA HANDLING PROTEINS IN BRAIN
LIPID SENSING AND NERVOUS CONTROL OF ENERGY
BALANCE
Since free FAs are not primary metabolic fuel for neurons, their
role in brain metabolism remained questionable for decades.
However, accumulating evidence demonstrated that FAs are used
in specific areas of CNS as cellular messengers which inform “FA
sensitive neurons” about energy status of the body (Migrenne
et al., 2011). This phenomenon, named “brain lipid sensing” as
an analogy with glucosensing, is involved in the control of feed-
ing behavior, hepatic glucose production, and insulin secretion
(Obici et al., 2003; Cruciani-Guglielmacci et al., 2004). Increasing
evidence show that CD36 may act as receptor, rather than a trans-
porter, for long chain FAs. In fact, El-Yassimi et al. showed that
linoleic acid binding on CD36-positive gustatory cells induced
src-kinases phosphorylation, calcium intracellular concentration
changes and serotonin and dopamine release (El-Yassimi et al.,
2008; Gaillard et al., 2008). These events could send nervous sig-
nals to the brain and induce peripheral modifications. In the
brain, Levin et al. showed that different neuronal groups in
hypothalamus responded differently to glucose or oleic acid (Le
Foll et al., 2009). Indeed some neurons are able to increase or
decrease their activity in response to oleic acid. The addition
of sulfosuccinimidyl oleate (CD36 inhibitor) or triacsin C (ACS
inhibitor) on freshly differentiated neurons lead to alteration of
the excitatory or inhibitory effects, indicating the involvement
of these proteins in central FA detection (Le Foll et al., 2009).
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In addition, studies suggest that hypothalamic FA sensitive neu-
rons are dependent on the metabolic state and display different
responses during fasting versus overfed state (Le Foll et al., 2009;
Migrenne et al., 2011). Energy status could also modify the
FA transport to the CNS regarding to brain needs. For exam-
ple, fasting induces a 30% decrease in glucose uptake and a
300% increase in palmitate uptake in hypothalamus, which is
correlated with plasma changes (hypoglycemia and plasma FA
increase) (Kasser et al., 1986). In our laboratory, we showed that
hypothalamic CD36 expression was decreased about −40% after
48 h-fasting and increased about +36% after 2 months of high
fat diet, suggesting that the metabolic status can modulate brain
CD36 expression (unpublished observations). Variations of CD36
expression could modulate lipid signaling in the brain and par-
ticipate to the regulation of energy homeostasis. Dysfunction of
these FA sensitive neurons could provide, at least in part, an
early mechanism underlying the impairment of neural control
of energy and glucose homeostasis and the development of obe-
sity and type 2 diabetes in predisposed subjects (Elmquist and
Marcus, 2003).
Moreover, recent studies show that hypertriglyceridemia,
observed in obesity, is associated with cognitive impairments
(Farr et al., 2008). Obese mice show impaired acquisition in cog-
nitive paradigms like elevated plus-maze test, a phenomenon that
can be corrected by lowering triglycerides. In addition, rats on
high energy diet show a reduced hippocampal synaptic plasticity
and an impairment of cognitive function (Stranahan et al., 2008).
We can suppose that a defect in brain lipid sensing ability relayed
by specific FA handling protein deficiency could induce cogni-
tive impairment. For example, CD36 null mice show a deficit in
learning ability (Abumrad et al., 2005) whereas there were no sig-
nificant differences in brain AA and DHA compared to control
mice suggesting that other mechanisms than brain composition
are involved in this phenotype.
CONCLUSION
A better understanding of the central role of FA handling proteins
could provide important clues for the identification of new thera-
peutic targets for the prevention and treatment of both metabolic
and cognitive diseases.
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